A PHASE II, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF INAVOLISIB PLUS RIBOCICLIB PLUS FULVESTRANT VERSUS PLACEBO PLUS RIBOCICLIB PLUS FULVESTRANT IN PATIENTS WITH ENDOCRINE-RESISTANT HORMONE-RECEPTOR-POSITIVE, HER2-NEGATIVE ADVANCED BREAST CANCER WITH CHROMOSOME 8P LOSS AND WITHOUT A PIK3CA MUTATION (PROTOCOL NUMBER: CO46274)
Phase: Phase II clinical trials
Principal Investigator: Prof. Vernieri Claudio
Main Facility: Oncologia Medica 1
Drug: Inavolisib + Fulvestrant + Ribociclib vs Placebo + Fulvestrant + Ribociclib
Pathologies: Breast cancer
ClinicalTrials.gov: Read the details about clinical trials
A randomized, multicenter, double-blind Phase 2 clinical trial using the investigational treatment Inavolisib + Fulvestrant + Ribociclib versus Placebo + Fulvestrant + Ribociclib in patients with HR+, HER2- locally advanced, unresectable and/or metastatic breast cancer. The study will enroll patients whose breast cancer does not harbor a PIK3CA mutation but has loss of chromosome 8p (i.e., loss of chr8p).
Last update: 14/07/2026